RxDoctor Payments Data

John McCollum, MD

General Practice · New Salisbury, INNPI 1750389318

Payments from drug & device makers

$317in general payments, 2019–2025

Across 18 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$56
  • Amgen$53
  • Novo Nordisk$51
  • Lilly USA, LLC$49
  • GSK$29
  • Pfizer$28
  • plus $52 from 3 others

What the payments were for

  • Food & beverage$317100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott1$56
Amgen3$53
Novo Nordisk3$51
Lilly USA, LLC3$49
GSK2$29
Pfizer2$28
AstraZeneca2$24
Novartis1$15
Merck1$12

How this compares

$317 in reported general payments places this provider in the 60th percentile of 1,558 general practice providers in Indiana.

See all general practice providers in Indiana

Medicare billing

Part B allowed, 2024
$64,350
Medicare patients
171
Services billed
943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban88$67,185
JanuviaSitagliptin Phosphate43$50,412
JardianceEmpagliflozin39$42,273
FarxigaDapagliflozin Propanediol43$32,331
OzempicSemaglutide21$21,356
XareltoRivaroxaban26$20,136
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$15,152
Atorvastatin Calcium334$2,508
Colestipol Hcl30$2,210
Potassium Chloride89$1,832
Metoprolol Succinate155$1,813
Celecoxib33$1,720
Omeprazole163$1,609
Albuterol Sulfate HfaAlbuterol Sulfate71$1,388
Gabapentin71$1,339

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$28$67,18588 claims
MerckJanuvia$12$50,41243 claims
AstraZenecaFarxiga$24$32,33143 claims
Novo NordiskOzempic$51$21,35621 claims
GSKTrelegy Ellipta$29$15,15219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,558 general practice providers in Indiana.

Other general practice in New Salisbury

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →